Access the full text.
Sign up today, get DeepDyve free for 14 days.
Tatsu Matsuzaki, Eri Iwami, Kotaro Sasahara, Aoi Kuroda, T. Nakajima, T. Terashima (2019)
A case report of metastatic lung adenocarcinoma with long-term survival for over 11 yearsMedicine, 98
Kierstin Utter, Chloe Goldman, S. Weiss, R. Shapiro, R. Berman, M. Wilson, A. Pavlick, I. Osman (2017)
Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the LiteratureOncology, 93
Douglas Johnson, J. Roszik, A. Shoushtari, Z. Eroglu, J. Balko, C. Higham, I. Puzanov, S. Patel, J. Sosman, S. Woodman (2016)
Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrumPigment Cell & Melanoma Research, 29
M. Sanchez-Cespedes, P. Parrella, M. Esteller, S. Nomoto, B. Trink, J. Engles, W. Westra, J. Herman, D. Sidransky (2002)
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.Cancer research, 62 13
A. Goodman, S. Kato, L. Bazhenova, S. Patel, G. Frampton, V. Miller, P. Stephens, G. Daniels, R. Kurzrock (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse CancersMolecular Cancer Therapeutics, 16
A. Gadducci, M. Guerrieri (2017)
Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.Anticancer research, 37 11
J. Sheu, Chun-Hung Hua, L. Wan, Ying-Ju Lin, M. Lai, Hsien‐Chang Tseng, N. Jinawath, M. Tsai, N. Chang, Chin-Fen Lin, Chyi-chyang Lin, L. Hsieh, Tian-Li Wang, I. Shih, F. Tsai (2009)
Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma.Cancer research, 69 6
F. Skoulidis, M. Goldberg, D. Greenawalt, M. Hellmann, M. Awad, J. Gainor, A. Schrock, R. Hartmaier, S. Trabucco, L. Gay, Siraj Ali, J. Elvin, G. Singal, J. Ross, D. Fabrizio, P. Szabo, Han Chang, A. Sasson, S. Srinivasan, S. Kirov, J. Szustakowski, P. Vitazka, R. Edwards, J. Bufill, N. Sharma, S. Ou, N. Peled, D. Spigel, H. Rizvi, E. Aguilar, B. Carter, J. Erasmus, D. Halpenny, A. Plodkowski, N. Long, M. Nishino, W. Denning, Ana Galán‐Cobo, Haifa Hamdi, Taghreed Hirz, P. Tong, Jing Wang, J. Rodriguez-Canales, P. Villalobos, E. Parra, N. Kalhor, L. Sholl, J. Sauter, A. Jungbluth, M. Mino‐Kenudson, Roxana Azimi, Y. Elamin, Jianjun Zhang, G. Leonardi, F. Jiang, Kwok-kin Wong, J. Lee, V. Papadimitrakopoulou, I. Wistuba, V. Miller, G. Frampton, J. Wolchok, A. Shaw, P. Jänne, P. Stephens, C. Rudin, W. Geese, L. Albacker, J. Heymach (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.Cancer discovery, 8 7
Liang Cheng, A. López-Beltran, F. Massari, G. MacLennan, R. Montironi (2017)
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicineModern Pathology, 31
Anshuman Panda, A. Betigeri, K. Subramanian, J. Ross, D. Pavlick, Siraj Ali, P. Markowski, A. Silk, H. Kaufman, E. Lattime, J. Mehnert, R. Sullivan, C. Lovly, J. Sosman, Douglas Johnson, G. Bhanot, S. Ganesan (2017)
Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors.JCO precision oncology, 2017
M. Sanchez-Cespedes (2007)
A role for LKB1 gene in human cancer beyond the Peutz–Jeghers syndromeOncogene, 26
F. Petrelli, G. Tomasello, S. Barni, V. Lonati, R. Passalacqua, M. Ghidini (2017)
Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literatureBreast Cancer Research and Treatment, 166
S. Vranić, J. Palazzo, Souzan Sanati, Elena Florento, E. Contreras, J. Xiu, J. Swensen, Z. Gatalica (2019)
Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the BreastClinical Breast Cancer, 19
M. Takeda, K. Nakagawa (2019)
First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?International Journal of Molecular Sciences, 20
S. Ke, Hu Qiu, Jiamei Chen, W. Shi, Yongshun Chen (2018)
Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain MetastasesCurrent Medical Science, 38
D. Robinson, Yi-Mi Wu, R. Lonigro, Pankaj Vats, E. Cobain, Jessica Everett, Xuhong Cao, Erica Rabban, Chandan Kumar-Sinha, V. Raymond, S. Schuetze, A. Alva, J. Siddiqui, R. Chugh, F. Worden, M. Zalupski, J. Innis, R. Mody, S. Tomlins, David Lucas, L. Baker, N. Ramnath, A. Schott, Daniel Hayes, J. Vijai, K. Offit, E. Stoffel, J. Roberts, David Smith, L. Kunju, M. Talpaz, M. Cieslik, A. Chinnaiyan (2017)
Integrative Clinical Genomics of Metastatic CancerNature, 548
R. Bose, Shyam Kavuri, Adam Searleman, W. Shen, D. Shen, D. Koboldt, J. Monsey, Nicholas Goel, Adam Aronson, Shunqiang Li, Cynthia Ma, L. Ding, E. Mardis, M. Ellis (2013)
Activating HER2 mutations in HER2 gene amplification negative breast cancer.Cancer discovery, 3 2
Z. Gatalica, J. Xiu, J. Swensen, S. Vranić (2018)
Molecular characterization of cancers with NTRK gene fusionsModern Pathology, 32
Ji-yeon Kim, Eunjin Lee, Kyunghee Park, W. Park, Hae Jung, J. Ahn, Y. Im, Yeon-Hee Park (2017)
Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genesOncotarget, 8
A. Bombonati, M. Lerwill (2012)
Metastases to and from the Breast.Surgical pathology clinics, 5 3
Lih-Mei Liao, Xiaoyu Ji, M. Ge, Qiong Zhan, Ruo-fan Huang, Xiaohua Liang, Xinli Zhou (2018)
Characterization of genetic alterations in brain metastases from non‐small cell lung cancerFEBS Open Bio, 8
K. Tsuruoka, H. Horinouchi, Y. Goto, S. Kanda, Y. Fujiwara, H. Nokihara, N. Yamamoto, K. Asakura, K. Nakagawa, H. Sakurai, Shun-ichi Watanabe, K. Tsuta, Y. Ohe (2017)
PD-L1 expression in neuroendocrine tumors of the lung.Lung cancer, 108
J. Bae, Yoon Choi, Dae Kim, Ji Lee, H. Jang, Joo Lee, Heesu Kim, B. Oh, M. Roh, K. Nam, K. Chung (2015)
Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies.Journal of the American Academy of Dermatology, 72 1
H. Kim, J. Lee, S. Nam, C. Ock, J. Moon, C. Yoo, G. Lee, Ji-Youn Han (2018)
Association of PD‐L1 Expression with Tumor‐Infiltrating Immune Cells and Mutation Burden in High‐Grade Neuroendocrine Carcinoma of the LungJournal of Thoracic Oncology, 13
E. Frinton, D. Tong, J. Tan, G. Read, V. Kumar, S. Kennedy, C. Lim, R. Board (2017)
Metastatic melanoma: prognostic factors and survival in patients with brain metastasesJournal of Neuro-Oncology, 135
Upasana Joneja, S. Vranić, J. Swensen, R. Feldman, W. Chen, Jeffrey Kimbrough, N. Xiao, S. Reddy, J. Palazzo, Z. Gatalica (2016)
Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1Journal of Clinical Pathology, 70
N. Priedigkeit, R. Hartmaier, Yijing Chen, D. Varešlija, A. Basudan, R. Watters, Roby Thomas, J. Leone, P. Lucas, R. Bhargava, R. Hamilton, J. Chmielecki, S. Puhalla, N. Davidson, S. Oesterreich, A. Brufsky, L. Young, Adrian Lee (2017)
Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain MetastasesJAMA Oncology, 3
W. Wen, W. Chen, Nick Xiao, Ryan Bender, A. Ghazalpour, Zheng Tan, J. Swensen, S. Millis, G. Basu, Z. Gatalica, M. Press (2015)
Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.The Journal of molecular diagnostics : JMD, 17 5
Genevieve Kaunitz, T. Cottrell, Mohammed Lilo, Valliammai Muthappan, Jessica Esandrio, S. Berry, Haiying Xu, A. Ogurtsova, R. Anders, A. Fischer, S. Kraft, M. Gerstenblith, C. Thompson, K. Honda, J. Cuda, C. Eberhart, J. Handa, E. Lipson, J. Taube (2017)
Melanoma subtypes demonstrate distinct PD-L1 expression profiles.Laboratory investigation; a journal of technical methods and pathology, 97 9
Xiao-wei Xu, C. Angelis, K. Burke, A. Nardone, Huizhong Hu, L. Qin, J. Veeraraghavan, Vidyalakshmi Sethunath, Laura Heiser, Nicholas Wang, C. Ng, Edward Chen, Alexander Renwick, Tao Wang, Sarmistha Nanda, M. Shea, Tamika Mitchell, M. Rajendran, Ian Waters, Daniel Zabransky, K. Scott, C. Gutierrez, C. Nagi, F. Geyer, G. Chamness, B. Park, C. Shaw, S. Hilsenbeck, M. Rimawi, Joe Gray, B. Weigelt, J. Reis-Filho, C. Osborne, R. Schiff (2017)
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast CancerClinical Cancer Research, 23
Z. Gatalica, J. Xiu, J. Swensen, S. Vranić (2018)
Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.European journal of cancer, 94
T. Powles, J. Eder, G. Fine, F. Braiteh, Y. Loriot, C. Cruz, J. Bellmunt, H. Burris, D. Petrylak, S. Teng, Xiao-dong Shen, Z. Boyd, P. Hegde, Daniel Chen, N. Vogelzang (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature, 515
Antonio Wolff, M. Hammond, David Hicks, M. Dowsett, Lisa Mcshane, Kimberly Allison, D. Allred, John Bartlett, M. Bilous, P. Fitzgibbons, W. Hanna, Robert Jenkins, P. Mangu, S. Paik, Edith Perez, Michael Press, Patricia Spears, Gail Vance, G. Viale, Daniel Hayes (2014)
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Archives of pathology & laboratory medicine, 138 2
S. Patel, Dae Kim, C. Lacey, P. Hwu (2016)
GNA11 Mutation in a Patient With Cutaneous Origin MelanomaMedicine, 95
X. Sheng, Y. Kong, Yiqian Li, Qiannan Zhang, L. Si, C. Cui, Z. Chi, B. Tang, L. Mao, B. Lian, Xuan Wang, Xieqiao Yan, Si-ming Li, J. Dai, Jun Guo (2016)
GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis.European journal of cancer, 65
R. Jeselsohn, Gilles Buchwalter, C. Angelis, Myles Brown, R. Schiff (2015)
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancerNature Reviews Clinical Oncology, 12
S. Schnitt (2008)
Biopsy Interpretation of the Breast
Xinxin Zhu, Ling Zhao, J. Lang (2018)
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian CancerInternational Journal of Gynecological Cancer, 28
A. Vanderwalde, D. Spetzler, N. Xiao, Z. Gatalica, J. Marshall (2018)
Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patientsCancer Medicine, 7
A. Koch, A. Richter-Marot, M. Wissler, A. Baratte, C. Mathelin (2013)
[Mammary metastasis of extramammary cancers: current knowledge and diagnostic difficulties].Gynecologie, obstetrique & fertilite, 41 11
T. Jiang, Q. Chu, Hui-juan Wang, F. Zhou, G. Gao, Xiaoxia Chen, Xue-Fei Li, Chao Zhao, Qinghua Xu, Wei Li, Fengying Wu, A. Xiong, J. Zhao, Ya-ping Xu, C. Su, S. Ren, Caicun Zhou, F. Hirsch (2018)
EGFR‐TKIs plus local therapy demonstrated survival benefit than EGFR‐TKIs alone in EGFR‐mutant NSCLC patients with oligometastatic or oligoprogressive liver metastasesInternational Journal of Cancer, 144
P. Ng, Jun Li, K. Jeong, S. Shao, Hu Chen, Y. Tsang, Sohini Sengupta, Zixing Wang, V. Bhavana, Richard Tran, Stephanie Soewito, Darlan Minussi, D. Moreno, Kathleen Kong, T. Dogruluk, Hengyu Lu, Jianjiong Gao, Collin Tokheim, D. Zhou, Amber Johnson, Jia Zeng, C. Ip, Z. Ju, M. Wester, Shuangxing Yu, Yongsheng Li, C. Vellano, N. Schultz, R. Karchin, L. Ding, Yiling Lu, L. Cheung, Ken Chen, K. Shaw, F. Meric-Bernstam, K. Scott, S. Yi, Nidhi Sahni, Han Liang, G. Mills (2018)
Systematic Functional Annotation of Somatic Mutations in Cancer.Cancer cell, 33 3
L. Carbognin, S. Pilotto, M. Milella, V. Vaccaro, M. Brunelli, A. Caliò, F. Cuppone, I. Sperduti, D. Giannarelli, M. Chilosi, V. Bronte, A. Scarpa, E. Bria, G. Tortora (2015)
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary CancersPLoS ONE, 10
F. Egberts, I. Bergner, S. Krüger, J. Haag, HM Behrens, Axel Hauschild, Christoph Röcken (2014)
Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.Annals of oncology : official journal of the European Society for Medical Oncology, 25 1
Asad Javed, D. Arguello, Curtis Johnston, Z. Gatalica, M. Terai, R. Weight, M. Orloff, M. Mastrangelo, Takami Sato (2017)
PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.Immunotherapy, 9 16
J. Rubinstein, M. Sznol, A. Pavlick, S. Ariyan, E. Cheng, Antonella Bacchiocchi, H. Kluger, D. Narayan, R. Halaban (2010)
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032Journal of Translational Medicine, 8
M. Hammond, Daniel Hayes, M. Dowsett, D. Allred, K. Hagerty, S. Badve, P. Fitzgibbons, G. Francis, Neil Goldstein, M. Hayes, David Hicks, S. Lester, R. Love, P. Mangu, L. McShane, K. Miller, C. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, Jared Schwartz, F. Sweep, S. Taube, E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. Williams, J. Wittliff, Antonio Wolff (2010)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.Archives of pathology & laboratory medicine, 134 6
Shyam Kavuri, N. Jain, F. Galimi, F. Cottino, S. Leto, Giorgia Migliardi, Adam Searleman, W. Shen, J. Monsey, L. Trusolino, S. Jacobs, A. Bertotti, R. Bose (2015)
HER2 activating mutations are targets for colorectal cancer treatment.Cancer discovery, 5 8
K. Kamposioras, G. Pentheroudakis, D. Pectasides, N. Pavlidis (2011)
Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature.Critical reviews in oncology/hematology, 78 2
A. Russo, T. Franchina, G. Ricciardi, V. Smiroldo, M. Picciotto, M. Zanghì, C. Rolfo, V. Adamo (2017)
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.Critical reviews in oncology/hematology, 117
(2017)
Metastatic ER+ Breast Cancer's Genomic Landscape.Cancer discovery, 7 2
R. Kancha, N. Bubnoff, C. Peschel, J. Duyster (2009)
Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted TherapyClinical Cancer Research, 15
J. Taube, A. Klein, J. Brahmer, Haiying Xu, Xiaoyu Pan, J. Kim, Lieping Chen, D. Pardoll, S. Topalian, R. Anders (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 TherapyClinical Cancer Research, 20
Hammond (2010)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerJ Clin Oncol, 28
S. Ribero, R. Pampena, V. Bataille, E. Moscarella, L. Thomas, P. Quaglino, C. Potenza, A. Akkooi, A. Testori, P. Nathan, S. Puig, I. Zalaudek, G. Argenziano, C. Longo (2017)
Unknown Primary Melanoma: Worldwide Survey on Clinical ManagementDermatology, 232
L. Angus, N. Beije, A. Jager, J. Martens, S. Sleijfer (2017)
ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.Cancer treatment reviews, 52
C. Ng, F. Bidard, S. Piscuoglio, F. Geyer, R. Lim, Ino Bruijn, R. Shen, F. Pareja, Samuel Berman, Lu Wang, J. Pierga, A. Vincent-Salomon, A. Viale, L. Norton, B. Sigal, B. Weigelt, P. Cottu, J. Reis-Filho (2017)
Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their MetastasesClinical Cancer Research, 23
A. Midha, S. Dearden, R. McCormack (2015)
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).American journal of cancer research, 5 9
T. Ota, Y. Hasegawa, A. Okimura, Katsuya Sakashita, T. Sunami, K. Yukimoto, Ryugo Sawada, K. Sakamoto, M. Fukuoka (2018)
Breast metastasis from EGFR‐mutated lung adenocarcinoma: A case report and review of the literatureClinical Case Reports, 6
A. Schultheis, A. Scheel, Luka Ozretić, J. George, Roman Thomas, T. Hagemann, T. Zander, J. Wolf, R. Buettner (2015)
PD-L1 expression in small cell neuroendocrine carcinomas.European journal of cancer, 51 3
P. Savoia, P. Fava, S. Osella-Abate, T. Nardò, A. Comessatti, P. Quaglino, M. Bernengo (2010)
Melanoma of unknown primary site: a 33-year experience at the Turin Melanoma CentreMelanoma Research, 20
Supplemental Digital Content is available in the text.
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Oct 11, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.